江苏亚虹医药科技股份有限公司关于使用部分暂时闲置募集资金进行现金管理的公告

Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. plans to utilize part of its temporarily idle raised funds for cash management, aiming to enhance fund efficiency while ensuring the safety of the raised funds and the implementation of investment projects [1][2]. Cash Management Overview - The company intends to use a maximum of RMB 1.2 billion (including the amount) of temporarily idle raised funds for cash management, with a validity period of 12 months from the date of the board's approval [2][8]. - The cash management aims to increase returns for the company and its shareholders while not affecting the normal operation of the fundraising investment projects [2][12]. Investment Details - The investment will focus on high-security, high-liquidity financial products sold by qualified financial institutions, including agreement deposits, time deposits, notice deposits, large certificates of deposit, structured deposits, and income certificates [4][8]. - The company will not use these funds for securities investment purposes [4]. Implementation and Oversight - The board has authorized the chairman to make investment decisions and sign relevant contracts within the approved limits and timeframe, with the finance department responsible for implementation [5][8]. - The company will adhere to strict regulatory requirements and maintain a separation of decision-making, execution, and supervision functions to ensure fund safety [10]. Impact on the Company - The use of temporarily idle raised funds for cash management is expected to improve fund efficiency and provide good investment returns for the company and its shareholders, without affecting daily cash flow needs or the normal operation of fundraising projects [12]. Opinions from Intermediaries - The sponsor, CITIC Securities Co., Ltd., has reviewed the cash management plan and found it compliant with relevant laws and regulations, expressing no objections to the company's decision [12].